LAS VEGAS, March 15, 2018 (GLOBE NEWSWIRE) — BioAdaptives, Inc., a fully-reporting public company trading under the ticker symbol BDPT (OTC PINK:BDPT) announced that Mr. Kim D. Southworth has assumed the position of Chief Executive Officer of the Company upon the resignation of Mr. Christopher Hall. Dr. Edward E Jacobs, Jr. has been selected to be the Company’s Scientific Director.

Both Mr. Southworth and Dr. Jacobs have also been appointed to the Board replacing Mr. Barry Epling, who has resigned. Epling and Ferris Holding, Inc separately and together are now beneficial owners of less than 10% of the Company’s stock.

In announcing the changes, Southworth said, “I am pleased for this opportunity to guide the Company in forwarding its research, development and finally bringing a proprietary line of products to market.  BioAdaptives is also actively looking at acquisitions both in US and Internationally for companies in the research, development, and manufacturing of dietary supplements and functional food.”

Southworth further added, “We are also in the process of finishing the accounting to bring the Company current in its reporting.”

Dr. Jacobs commented, “I am pleased to join BioAdaptives, Inc to oversee its research, testing, trials and clinical studies.  We look forward to bringing to market a unique, effective line of products for human and animal consumption.”

Biographical Information for Mr. Southworth and Dr. Jacobs can be found on the BioAdaptives’ website: www.bioadaptives.com

About BioAdaptives, Inc.

BioAdaptives, Inc. is a fully-reporting, public company trading on the OTC PINK under the symbol BDPT. The company is engaged in research and development in science-based nutraceutical products for human and animal consumption.

SAFE HARBOR ACT

Forward-Looking Statements: This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of BioAdaptives, Inc. and its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond BioAdaptives, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in BioAdaptives, Inc.’s filings with the Securities and Exchange Commission.

Investor Relations
BioAdaptives, Inc.
1-833-278-2378
ir@BioAdaptives.com

SOURCE: BioAdaptives, Inc.